Literature DB >> 18026953

Coinheritance of the different copy numbers of alpha-globin gene modifies severity of beta-thalassemia/Hb E disease.

Orapan Sripichai1, Thongperm Munkongdee, Chutima Kumkhaek, Saovaros Svasti, Pranee Winichagoon, Suthat Fucharoen.   

Abstract

beta-Thalassemia/Hb E patients show a range of clinical severities, from nearly asymptomatic to transfusion-dependent thalassemia major. This study investigated the clinical heterogeneity and hematologic parameters obtained in the large cohort of 925 Thai beta 0-thalassemia/Hb E patients. Coinheritance of alpha-thalassemia with beta 0-thalassemia/Hb E produces a milder clinical phenotype in contrast to an interaction of alpha-globin gene triplication in severe thalassemia. The mean steady-state Hb was also higher, whereas the mean corpuscular volume and the percentage of Hb F were markedly lower in the former group. This finding demonstrates that the genetic combination leading to the more/less degree of alpha- to non-alpha-globin chains imbalance is indeed the cause of the severe/mild thalassemia phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026953     DOI: 10.1007/s00277-007-0407-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

1.  A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E.

Authors:  Manit Nuinoon; Wattanan Makarasara; Taisei Mushiroda; Iswari Setianingsih; Pustika Amalia Wahidiyat; Orapan Sripichai; Natsuhiko Kumasaka; Atsushi Takahashi; Saovaros Svasti; Thongperm Munkongdee; Surakameth Mahasirimongkol; Chayanon Peerapittayamongkol; Vip Viprakasit; Naoyuki Kamatani; Pranee Winichagoon; Michiaki Kubo; Yusuke Nakamura; Suthat Fucharoen
Journal:  Hum Genet       Date:  2010-03       Impact factor: 4.132

2.  Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.

Authors:  Giulia Pavani; Anna Fabiano; Marine Laurent; Fatima Amor; Erika Cantelli; Anne Chalumeau; Giulia Maule; Alexandra Tachtsidi; Jean-Paul Concordet; Anna Cereseto; Fulvio Mavilio; Giuliana Ferrari; Annarita Miccio; Mario Amendola
Journal:  Blood Adv       Date:  2021-03-09

3.  Imbalanced globin chain synthesis determines erythroid cell pathology in thalassemic mice.

Authors:  Kanitta Srinoun; Saovaros Svasti; Worrakavee Chumworathayee; Jim Vadolas; Phantip Vattanaviboon; Suthat Fucharoen; Pranee Winichagoon
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

4.  Interaction of malaria with a common form of severe thalassemia in an Asian population.

Authors:  A O'Donnell; A Premawardhena; M Arambepola; R Samaranayake; S J Allen; T E A Peto; C A Fisher; J Cook; P H Corran; Nancy F Olivieri; D J Weatherall
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

Review 5.  α-Globin as a molecular target in the treatment of β-thalassemia.

Authors:  Sachith Mettananda; Richard J Gibbons; Douglas R Higgs
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

6.  α0-thalassemia in affected fetuses with hemoglobin E-β0-thalassemia disease in a high-risk population in Thailand.

Authors:  Supawadee Yamsri; Simaporn Prommetta; Hataichanok Srivorakun; Wachiraporn Taweenan; Kanokwan Sanchaisuriya; Attawut Chaibunruang; Goonnapa Fucharoen; Supan Fucharoen
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 7.  Hb E/beta-thalassaemia: a common & clinically diverse disorder.

Authors:  Nancy F Olivieri; Zahra Pakbaz; Elliott Vichinsky
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

8.  Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies.

Authors:  Coralea Stephanou; Stella Tamana; Anna Minaidou; Panayiota Papasavva; Marina Kleanthous; Petros Kountouris
Journal:  J Clin Med       Date:  2019-11-09       Impact factor: 4.241

Review 9.  Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia.

Authors:  Nur Atikah Zakaria; Md Asiful Islam; Wan Zaidah Abdullah; Rosnah Bahar; Abdul Aziz Mohamed Yusoff; Ridhwan Abdul Wahab; Shaharum Shamsuddin; Muhammad Farid Johan
Journal:  Biomolecules       Date:  2021-05-18

Review 10.  Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients.

Authors:  Hanan Kamel M Saad; Alawiyah Awang Abd Rahman; Azly Sumanty Ab Ghani; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abdullah Saleh Al-Wajeeh; Hamid Ali Nagi Al-Jamal
Journal:  Biomedicines       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.